DLK Investment Management LLC Boosts Stake in Amgen Inc. (NASDAQ:AMGN)

DLK Investment Management LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 0.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,224 shares of the medical research company’s stock after acquiring an additional 115 shares during the period. Amgen makes up about 2.4% of DLK Investment Management LLC’s portfolio, making the stock its 16th largest holding. DLK Investment Management LLC’s holdings in Amgen were worth $6,194,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Boone Capital Management LLC increased its stake in shares of Amgen by 3.4% during the fourth quarter. Boone Capital Management LLC now owns 101,508 shares of the medical research company’s stock worth $29,236,000 after purchasing an additional 3,382 shares in the last quarter. Bontempo Ohly Capital Mgmt LLC increased its stake in Amgen by 0.8% during the 4th quarter. Bontempo Ohly Capital Mgmt LLC now owns 8,506 shares of the medical research company’s stock worth $2,450,000 after buying an additional 67 shares in the last quarter. Gotham Asset Management LLC raised its holdings in shares of Amgen by 28.4% during the fourth quarter. Gotham Asset Management LLC now owns 41,390 shares of the medical research company’s stock valued at $11,921,000 after acquiring an additional 9,164 shares during the last quarter. Groupama Asset Managment purchased a new position in shares of Amgen in the fourth quarter valued at approximately $10,955,000. Finally, Grayhawk Investment Strategies Inc. acquired a new stake in shares of Amgen in the fourth quarter worth approximately $454,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 1.0 %

AMGN traded up $3.19 on Friday, hitting $324.20. 339,127 shares of the company were exchanged, compared to its average volume of 2,460,375. The firm has a 50-day moving average price of $326.17 and a two-hundred day moving average price of $310.22. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The company has a market cap of $174.20 billion, a price-to-earnings ratio of 55.25, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter in the previous year, the company posted $5.00 earnings per share. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.78%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is 154.91%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on AMGN shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Bank of America upped their price objective on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Morgan Stanley cut their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $380.00 price objective (up previously from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $326.30.

Get Our Latest Report on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.